Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2021-04-08 Sale |
2021-04-15 7:09 pm |
Prelude Therapeutics Inc | PRLD | Mauro David J Chief Medical Officer |
9,617 | $38.35 | $368,852 | 277,610 (Direct) |
View |
| 2021-04-07 Sale |
2021-04-09 5:55 pm |
Prelude Therapeutics Inc | PRLD | Scherle Peggy Chief Scientific Officer |
15,370 | $39.31 | $604,144 | 244,010 (Direct) |
View |
| 2021-04-07 Sale |
2021-04-09 5:53 pm |
Prelude Therapeutics Inc | PRLD | Pierce Christopher EVP and Chief of Business Oper |
828 | $40.08 | $33,188 | 11,568 (Direct) |
View |
| 2021-04-07 Sale |
2021-04-09 5:52 pm |
Prelude Therapeutics Inc | PRLD | Morosini Deborah EVP, Chief of Clinical Affairs |
1,000 | $40.04 | $40,043 | 8,090 (Direct) |
View |
| 2021-04-07 Sale |
2021-04-09 5:50 pm |
Prelude Therapeutics Inc | PRLD | Mauro David J Chief Medical Officer |
15,383 | $39.33 | $605,023 | 287,227 (Direct) |
View |
| 2020-09-25 Purchase |
2020-09-30 7:52 pm |
Prelude Therapeutics Inc | PRLD | Bonita David P Director 10% Owner |
1,236,800 | $19 | $23,499,200 | 23,248,793 (Indirect Direct) |
View |
| 2020-09-29 Purchase |
2020-09-30 6:37 pm |
Prelude Therapeutics Inc | PRLD | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director 10% Owner |
1,578,947 | $19 | $29,999,993 | 26,902,988 (Indirect) |
View |
| 2020-09-29 Purchase |
2020-09-29 8:11 pm |
Prelude Therapeutics Inc | PRLD | Combs Andrew EVP, Head of Chemistry |
1,000 | $19 | $19,000 | 260,380 (Direct) |
View |
| 2020-09-25 Purchase |
2020-09-29 8:10 pm |
Prelude Therapeutics Inc | PRLD | ORBIMED ADVISORS LLC OrbiMed Capital GP VI LLC ORBIMED CAPITAL LLC Director 10% Owner |
1,236,800 | $19 | $23,499,200 | 14,805,377 (Indirect) |
View |
| 2020-09-29 Purchase |
2020-09-29 8:09 pm |
Prelude Therapeutics Inc | PRLD | Dier Mardi Director |
10,000 | $19 | $190,000 | 10,000 (Direct) |
View |
| 2020-09-29 Purchase |
2020-09-29 8:08 pm |
Prelude Therapeutics Inc | PRLD | Morosini Deborah EVP, Chief of Clinical Affairs |
444 | $19 | $8,436 | 444 (Direct) |
View |
| 2020-09-29 Purchase |
2020-09-29 8:07 pm |
Prelude Therapeutics Inc | PRLD | Pierce Christopher EVP and Chief of Business Oper |
3,750 | $19 | $71,250 | 3,750 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2021-04-08 Exercise |
2021-04-15 7:09 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | Mauro David J Chief Medical Officer |
9,617 | $1.89 | 277,610 (Direct) |
View |
| 2021-04-08 Exercise |
2021-04-15 7:09 pm |
N/A 2029-06-16 |
Prelude Therapeutics Inc | PRLD | Mauro David J Chief Medical Officer |
9,617 | $0 | 277,610 (Direct) |
View |
| 2021-04-07 Option Award |
2021-04-09 5:55 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | Scherle Peggy Chief Scientific Officer |
15,370 | $1.43 | 244,010 (Direct) |
View |
| 2021-04-07 Exercise |
2021-04-09 5:55 pm |
N/A 2028-11-12 |
Prelude Therapeutics Inc | PRLD | Scherle Peggy Chief Scientific Officer |
15,370 | $0 | 244,010 (Direct) |
View |
| 2021-04-07 Exercise |
2021-04-09 5:53 pm |
N/A 2030-03-26 |
Prelude Therapeutics Inc | PRLD | Pierce Christopher EVP and Chief of Business Oper |
828 | $0 | 11,568 (Direct) |
View |
| 2021-04-07 Option Award |
2021-04-09 5:53 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | Pierce Christopher EVP and Chief of Business Oper |
828 | $1.89 | 11,568 (Direct) |
View |
| 2021-04-07 Exercise |
2021-04-09 5:52 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | Morosini Deborah EVP, Chief of Clinical Affairs |
1,000 | $1.89 | 8,090 (Direct) |
View |
| 2021-04-07 Exercise |
2021-04-09 5:52 pm |
N/A 2030-03-26 |
Prelude Therapeutics Inc | PRLD | Morosini Deborah EVP, Chief of Clinical Affairs |
1,000 | $0 | 8,090 (Direct) |
View |
| 2021-04-07 Exercise |
2021-04-09 5:50 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | Mauro David J Chief Medical Officer |
15,383 | $1.89 | 287,227 (Direct) |
View |
| 2021-04-07 Exercise |
2021-04-09 5:50 pm |
N/A 2029-06-16 |
Prelude Therapeutics Inc | PRLD | Mauro David J Chief Medical Officer |
15,383 | $0 | 287,227 (Direct) |
View |
| 2021-01-27 Exercise |
2021-01-29 7:04 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director 10% Owner |
5,188 | $12.85 | 9,335,951 (Indirect) |
View |
| 2021-01-27 Exercise |
2021-01-29 7:04 pm |
N/A 2030-09-01 |
Prelude Therapeutics Inc | PRLD | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director 10% Owner |
10,376 | $0 | 9,335,951 (Indirect) |
View |
| 2020-09-29 Conversion |
2020-09-30 7:52 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | Bonita David P Director 10% Owner |
27,775,930 | $0 | 23,248,793 (Indirect) |
View |
| 2020-09-24 Option Award |
2020-09-30 7:52 pm |
N/A 2030-09-01 |
Prelude Therapeutics Inc | PRLD | Bonita David P Director 10% Owner |
46,688 | $0 | 23,248,793 (Direct) |
View |
| 2020-09-29 Conversion |
2020-09-30 6:37 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director 10% Owner |
19,443,148 | $0 | 26,902,988 (Indirect) |
View |
| 2020-09-24 Option Award |
2020-09-30 6:37 pm |
N/A 2030-09-01 |
Prelude Therapeutics Inc | PRLD | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director 10% Owner |
46,688 | $0 | 26,902,988 (Indirect) |
View |
| 2020-09-29 Conversion |
2020-09-29 8:10 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | ORBIMED ADVISORS LLC OrbiMed Capital GP VI LLC ORBIMED CAPITAL LLC Director 10% Owner |
27,775,930 | $0 | 14,805,377 (Indirect) |
View |
| 2020-09-29 Conversion |
2020-09-29 8:06 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | Vaddi Krishna President, CEO |
167,229 | $0 | 2,020,948 (Indirect) |
View |
| 2020-09-24 Option Award |
2020-09-28 7:37 pm |
N/A 2030-09-23 |
Prelude Therapeutics Inc | PRLD | Sandor Victor Director |
3,458 | $0 | 3,458 (Direct) |
View |
| 2020-09-24 Option Award |
2020-09-28 7:35 pm |
N/A 2030-09-23 |
Prelude Therapeutics Inc | PRLD | Dier Mardi Director |
3,458 | $0 | 3,458 (Direct) |
View |
Ownership |
2020-09-24 7:32 pm |
N/A 2030-09-01 |
Prelude Therapeutics Inc | PRLD | Dier Mardi Director |
0 | $0 | 43,230 (Direct) |
View |
Ownership |
2020-09-24 7:30 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | Vaddi Krishna President, CEO |
0 | $0 | 4,553,094 (Direct) |
View |
Ownership |
2020-09-24 7:29 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director 10% Owner |
0 | $0 | 14,094,874 (Indirect) |
View |
Ownership |
2020-09-24 7:29 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | Scherle Peggy Chief Scientific Officer |
0 | $0 | 531,728 (Direct) |
View |
Ownership |
2020-09-24 7:28 pm |
N/A 2030-05-12 |
Prelude Therapeutics Inc | PRLD | Sandor Victor Director |
0 | $0 | 43,230 (Direct) |
View |
Ownership |
2020-09-24 7:27 pm |
N/A 2029-08-06 |
Prelude Therapeutics Inc | PRLD | Piper Brian Chief Financial Officer |
0 | $0 | 462,559 (Direct) |
View |
Ownership |
2020-09-24 7:26 pm |
N/A 2030-03-26 |
Prelude Therapeutics Inc | PRLD | Pierce Christopher EVP and Chief of Business Oper |
0 | $0 | 332,870 (Direct) |
View |
Ownership |
2020-09-24 7:24 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | ORBIMED ADVISORS LLC OrbiMed Capital GP VI LLC Director 10% Owner |
0 | $0 | 14,094,877 (Indirect) |
View |
Ownership |
2020-09-24 7:23 pm |
N/A 2030-03-26 |
Prelude Therapeutics Inc | PRLD | Morosini Deborah EVP, Chief of Clinical Affairs |
0 | $0 | 332,870 (Direct) |
View |
Ownership |
2020-09-24 7:21 pm |
N/A 2029-06-16 |
Prelude Therapeutics Inc | PRLD | Mauro David J Chief Medical Officer |
0 | $0 | 488,497 (Direct) |
View |
Ownership |
2020-09-24 7:20 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | FRIEDMAN PAUL A Director |
0 | $0 | 546,786 (Direct) |
View |
Ownership |
2020-09-24 7:07 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | Combs Andrew EVP, Head of Chemistry |
0 | $0 | 462,560 (Direct) |
View |
Ownership |
2020-09-24 7:05 pm |
N/A N/A |
Prelude Therapeutics Inc | PRLD | Bonita David P Director 10% Owner |
0 | $0 | 14,094,877 (Indirect) |
View |